Wasatch Advisors Inc. boosted its stake in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 53.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,533 shares of the biotechnology company’s stock after acquiring an additional 5,394 shares during the quarter. Wasatch Advisors Inc.’s holdings in Atara Biotherapeutics were worth $571,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Riverhead Capital Management LLC purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at approximately $100,000. SG Americas Securities LLC purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at approximately $107,000. Bank of Montreal Can purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at approximately $180,000. Principal Financial Group Inc. purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at approximately $214,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Atara Biotherapeutics during the 4th quarter valued at approximately $217,000. Hedge funds and other institutional investors own 98.58% of the company’s stock.

In related news, CEO Isaac E. Ciechanover sold 8,800 shares of the firm’s stock in a transaction on Tuesday, May 22nd. The stock was sold at an average price of $51.74, for a total transaction of $455,312.00. Following the transaction, the chief executive officer now directly owns 812,613 shares in the company, valued at $42,044,596.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Matthew K. Fust sold 12,286 shares of the firm’s stock in a transaction on Monday, May 14th. The stock was sold at an average price of $43.57, for a total value of $535,301.02. Following the transaction, the director now owns 19,820 shares in the company, valued at $863,557.40. The disclosure for this sale can be found here. Insiders have sold 169,400 shares of company stock worth $7,301,767 over the last 90 days. 10.60% of the stock is currently owned by company insiders.

Several equities analysts have recently commented on ATRA shares. BidaskClub upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, April 26th. Zacks Investment Research upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Tuesday, May 1st. ValuEngine upgraded Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Canaccord Genuity restated a “buy” rating and set a $70.00 price objective on shares of Atara Biotherapeutics in a research note on Tuesday, May 8th. Finally, Citigroup reduced their price objective on Atara Biotherapeutics from $25.00 to $23.00 and set a “sell” rating on the stock in a research note on Monday, June 11th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $43.17.

Shares of Atara Biotherapeutics opened at $38.10 on Friday, according to MarketBeat Ratings. Atara Biotherapeutics Inc has a 12-month low of $12.65 and a 12-month high of $54.45. The firm has a market cap of $1.67 billion, a P/E ratio of -9.53 and a beta of 2.55.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.17). analysts predict that Atara Biotherapeutics Inc will post -4.58 EPS for the current fiscal year.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Read More: Price to Earnings Ratio (PE), For Valuing Stocks

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.